A compound represented by formula the possible enantiomers, diastereomers and tautomers and pharmaceutically acceptable salts thereof, wherein one of Q 1 to Q 5 is a nitrogen atom and the remaining radicals are carbon atoms; R 1 is selected from the group consisting of H, C 1-10 alkyl, C 1-10 alkenyl, C 1-10 alkynyl, C 0-6 alkylene-C 3-10 cycloalkyl, C 0-6 alkylene-C 3-10 heterocycloalkyl, C 0-6 alkylene-5-membered heteroaromatic ring system containing 1, 2, or 3 heteroatoms independently selected from the group consisting of N, O and S wherein alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl and the 5-membered heteroaromatic ring system are unsubstituted or substituted with 1 to 6 substituents independently selected from the group consisting of OH, oxo, CN, O-C 1-6 alkyl, O-halo-C 1-6 alkyl, C 1-6 alkyl, halo-C 1-6 alkyl, halogen, COOR 10, CON(R 10) 2, SO 2 R 10, SO 2 N(R 10) 2, NR 10 COR 10, NR 10 SO 2 R 10 and N(R 10) 2; R 2 is selected from the group consisting of H, C 1-6 alkyl and halo-C 1-6 alkyl, or R 1 and R 2 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing an additional heteroatom selected from O, S, SO, SO 2 or NR 10, wherein the ring is unsubstituted or substituted with one to four substituents independently selected from halogen, oxo or C 1-6 -alkyl; R 3 is H, C 1-6 alkyl, halo-C 1-6 alkyl, CN or halogen wherein alkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of O-C 1-6 alkyl, O-halo-C 1-6 alkyl, oxo and OH; R 4 is SO 2 -(CR 8 R 8) y R 7 or (CR 8 R 8) x -R 11; R 5 is pyridinone, a 6-10 membered mono- or bicyclic aryl or a 5-14 membered mono-, bi- or tricyclic heteroaryl containing 1 to 4 heteroatoms independently selected from the group consisting of N, O and S wherein pyridinone, aryl and heteroaryl are unsubstituted or substituted with 1 to 5 substituents independently selected from halogen, CN, C 1-6 alkyl, C 1-6 alkenyl, C 1-6 alkynyl, halo-C 1-6 alkyl, OH, O-C 1-6 alkyl, O-halo-C 1-6 alkyl, C 3-10 cycloalkyl, O-C 3-10 cycloalkyl, COOR 9, C R 9, C N(R 9) 2, SO 2 -N(R 9) 2, SO 2 -R 9, C 3-10 heterocycloalkyl, phenyl, 5-6 membered heteroaryl containing 1 to 4 heteroatoms independently selected from N, O and S wherein alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, phenyl and heteroaryl are unsubstituted or substituted by 1 to 3 substituents independently selected from the group consisting of halogen, OH, oxo, =N-OH, =N-O-(C 1-6 alkyl), N(R 9) 2, O-C 1-6 alkyl; COOH, CON(R 9) 2, CN, NR 9 -COR 10, C 3-10 cycloalkyl, C 3-10 heterocycloalkyl, 6-10 membered mono- or bicyclic aryl or wherein two adjacent substituents may complete a 3- to 8-membered saturated or partially unsaturated ring containing carbon atoms and optionally containing 1 to 3 heteroatoms selected from O, S, SO, SO 2 or NR 10, wherein the ring is unsubstituted or substituted with one to four substituents independently selected from halogen, oxo, =N-OH, =N-O-(C 1-6 alkyl), OH, O-C 1-6 -alkyl, O-halo-C 1-6 -alkyl, C 1-6 -alkyl, C 3-6 -cycloalkyl and halo-C 1-6 -alkyl; R 6 is H, C 1-6 alkyl, halo-C 1-6 alkyl or halogen; R 7 is C 1-10 alkyl, C 3-10 cycloalkyl, C 3-10 heterocycloalkyl, 6-10 membered mono- or bicyclic aryl or 5-10 membered mono- or bicyclic heteroaryl wherein cycloalkyl, heterocycloalkyl, aryl and heteroaryl are unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of halogen, OH, O-C 1-6 alkyl, O-halo-C 1-6 alkyl, C 1-6 alkyl, halo-C 1-6 alkyl and NH 2 and wherein alkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of halogen, OH, O-C 1-6 alkyl, O-halo-C 1-6 alkyl and NH 2; R 8 is independently H, Alkyl, O-C 1-4 alkyl, halo-C 1-4 alkyl or halogen; R 9 is independently selected from H, C 1-6 alkyl, C 3-10 cycloalkyl, C 3-10 heterocycloalkyl, phenyl, 5-6 membered heteroaryl containing 1 to 4 heteroatoms independently selected from N, O and S wherein alkyl, cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 3 substituents selected from the group consisting of OH, O-C 1-6 alkyl, O-halo-C 1-6 alkyl, phenyl, heteroaryl, halogen, NH 2, NH(C 1-6 alkyl), N(C 1-6 alkyl) 2, C 3-10 heterocycloalkyl and C 3-10 cycloalkyl wherein cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of C 1-6 alkyl, halo-C 1-6 alkyl, OH, O-C 1-6 alkyl, O-halo-C 1-6 alkyl, phenyl, heteroaryl, halogen, NH 2, NH(C 1-6 alkyl), N(C 1-6 alkyl) 2 and C 3-10 cycloalkyl wherein phenyl and heteroaryl are unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of OH, O-C 1-6 alkyl, O-halo-C 1-6 alkyl, halogen, C 1-6 alkyl, halo-C 1-6 alkyl, NH 2, NH(C 1-6 alkyl), N(C 1-6 alkyl) 2 and C 3-10 cycloalkyl; R 10 is independently selected from H, C 1-6 alkyl, halo-C 1-6 alkyl and C 3-10 cycloalkyl; R 11 is C 2-10 alkyl, C 3-10 cycloalkyl, C 3-10 heterocycloalkyl, 6-10 membered mono- or bicyclic aryl or 5-10 membered mono- or bicyclic heteroaryl wherein alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of halogen, OH, oxo, O-C 1-6 alkyl, O-halo-C 1-6 alkyl, C 1-6 alkyl, halo-C 1-6 alkyl and NH 2; x is 1, 2 or 3; and y is 0, 1, or 2; with the proviso that for R 5 the 5-14 membered mono-, bi- or tricyclic heteroaryl containing ring is not and with the proviso that (CR 8 R 8) x -R 11 is not